In Madrid, lung cancer loses ground
At Europe’s cancer congress, Amgen and Roche cut the risk of death by half, or nearly.
· N° 7
Madrid, Saturday. Before thousands of oncologists gathered by the European Society for Medical Oncology, Amgen presents Imdelltra, combined with AstraZeneca’s Imfinzi, as first-line maintenance treatment in some patients with small-cell lung cancer: a 58% lower risk of death than with Imfinzi alone, according to Endpoints News, far beyond what analysts expected.
KRAS, the mutation where Roche outpaces its rivals
On Sunday, Roche detailed its next-generation inhibitor against the KRAS G12C mutation, found in a share of non-small-cell lung cancers: a 44% lower risk of death than the Amgen and Bristol Myers Squibb drugs aimed at the same target, in a head-to-head trial.
After the vaccine, the work begins
Moderna and Merck’s personalised melanoma vaccine filled the presidential symposium, “a triumph of science” according to Endpoints News. One shadow over the picture: according to an analysis cited by STAT, most cancer drugs approved in Europe do not bring a high clinical benefit. Is treating better always treating more?
Based on Endpoints News and STAT News